Ireland - English - HPRA (Health Products Regulatory Authority)

viatris healthcare limited - a/victoria/2570/2019 (h1n1)pdm09 - like strain (a/victoria/2570/2019, ivr-215) ; a/darwin/9/2021 (h3n2) - like strain (a/darwin/9/2021, ivr-228); b/phuket/3073/2013 -like strain (b/phuket/3073/2013, wild type); b/austria/1359417/2021 - like strain (b/michigan/01/2021, wild type) - suspension for injection in pre-filled syringe - influenza vaccines; influenza, inactivated, split virus or surface antigen

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - influenza virus haemagglutinin -

Ireland - English - HPRA (Health Products Regulatory Authority)

glaxosmithkline (ireland) limited - aluminium; hepatitis a antigen - suspension for injection in pre-filled syringe - 720 enzyme-linked immunosorbent assay unit - hepatitis vaccines; hepatitis a, inactivated, whole virus

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - live varicella vaccine, quantity: 1995 pfu; rubella virus, quantity: 1000 ccid50; measles virus, quantity: 1000 ccid50; mumps virus, quantity: 25119 ccid50 - diluent, not applicable - excipient ingredients: water for injections - priorix-tetra is indicated for active immunisation against measles, mumps, rubella and varicella from 9 months of age.

Ireland - English - HPRA (Health Products Regulatory Authority)

glaxosmithkline (ireland) limited - hepatitis b surface antigen, recominant - suspension for injection in pre-filled syringe - 10/0.5 microgram(s)/millilitre - hepatitis vaccines; hepatitis b, purified antigen

Ireland - English - HPRA (Health Products Regulatory Authority)

glaxosmithkline (ireland) limited - hepatitis b surface antigen, recominant - suspension for injection in pre-filled syringe - 20/1 microgram(s)/millilitre - hepatitis vaccines; hepatitis b, purified antigen

Ireland - English - HPRA (Health Products Regulatory Authority)

glaxosmithkline (ireland) limited - a/victoria/4897/2022 (h1n1)pdm09-like strain (a/victoria/4897/2022, ivr-238; a/darwin/9/2021 (h3n2)-like strain (a/darwin/6/2021, ivr-227); b/austria/1359417/2021 - like strain (b/austria/1359417/2021, bvr-26) [victoria lineage]; b/phuket/3073/2013 -like strain (b/phuket/3073/2013, wild type) - suspension for injection in pre-filled syringe - 15 international unit(s) - influenza vaccines; influenza, inactivated, split virus or surface antigen

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - varicella vaccine 2000 pfu (not less than); varicella vaccine 2000 pfu (not less than) - powder for injection with diluent - 2000 pfu - active: varicella vaccine 2000 pfu (not less than) excipient: albumin amino acids lactose monohydrate mannitol sorbitol water for injection active: varicella vaccine 2000 pfu (not less than) excipient: amino acids lactose mannitol sorbitol - varilrix is indicated for active immunisation and prophylaxis against varicella in healthy infants (from the age of 9 months), children, adolescents and adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - live varicella vaccine, quantity: 4000 pfu/ml; isoleucine, quantity: 0.355 mg; leucine, quantity: 0.432 mg - injection, powder for - excipient ingredients: lactose; sorbitol; mannitol; threonine; serine; proline; glycine; alanine; valine; methionine; tyrosine; phenylalanine; tryptophan; lysine hydrochloride; histidine; arginine - varilrix hsa-free is indicated for active immunisation against varicella of healthy subjects from 9 months of age. groups who would particularly benefit from vaccination include: non-immune adults, especially those in at-risk occupations such as health care workers, teachers and workers in children's day-care centres. non-immune parents of young children. non-immune household contacts, both adults and children, of immunocompromised patients with no history of the disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - live varicella vaccine, quantity: 4000 pfu/ml; isoleucine, quantity: 0.355 mg - injection, powder for - excipient ingredients: lactose; mannitol; sorbitol; threonine; serine; proline; glycine; alanine; valine; methionine; leucine; tyrosine; phenylalanine; tryptophan; lysine hydrochloride; histidine; arginine - varilrix hsa-free is indicated for active immunisation against varicella of healthy subjects from 9 months of age. groups who would particularly benefit from vaccination include: non-immune adults, especially those in at-risk occupations such as health care workers, teachers and workers in children's day-care centres. non-immune parents of young children. non-immune household contacts, both adults and children, of immunocompromised patients with no history of the disease.